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Solitary fibrous tumor of the pleura with hypoglycemia
associated with serum insulin-like growth factor II
Ayako Hirai, MD, and Ryoichi Nakanishi, MD, PhD, Kitakyusyu, Japan
Solitary fibrous tumor of the pleura (SFTP) is a rareneoplasm that accounts for 10% of pleural neoplasms.Although the majority of SFTPs have benign histologicfeatures, approximately 12% of them are malignant.1
Although more than half of patients with SFTP are free of
symptoms, large tumors cause respiratory symptoms such as dys-
pnea, cough, hemoptysis, and chest pain as a result of bronchial
compression, atelectasis, and obstructive pneumonia. Furthermore,
systemic symptoms, such as hypoglycemia and hypertrophic os-
teoarthropathy, and nonspecific symptoms, such as fever and fa-
tigue, are occasionally found in patients with SFTP.
The incidence of hypoglycemia has been reported to be ap-
proximately 4%. Although insulin-like growth factor II (IGF-II) is
considered to be related to the hypoglycemia, there are few reports
manifesting this relationship on the basis of specific data.1 We
herein describe a rare case of malignant SFTP with hypoglycemia
closely associated with serum IGF-II.
Clinical Summary
A 77-year-old man was admitted with cold sweating, cough, and
dyspnea. He had symptoms of finger clubbing and hypertrophic
osteoarthropathy.
Laboratory analyses on pulmonary functions at admission are
described in Table 1. Chest radiographs revealed a large consoli-
dation in the right middle and lower lung fields although a small
consolidation had been pointed out in the same fields 15 years
before. Computed tomographic scan of the chest with intravenous
contrast demonstrated the abnormal giant mass slightly compress-
ing the heart (Figure 1).
The patient had a diagnosis of SFTP by ultrasonically guided
percutaneous needle biopsy although bronchoscopy could not con-
firm the diagnosis. We performed an upper and middle bilobectomy
and a wedge resection of the lower lobe of the lung, infiltrated by this
tumor, although the patient had poor pulmonary function result-
ing from persistent obstructive
pneumonia. A complete resec-
tion was achieved with the aid
of video-assisted thoracoscopy
through the anterolateral thoracotomy.
The tumor measured 10.9  9.8  9.4 cm. On histologic
examination, the tumor exhibited a classic “pattern-less” pattern of
SFTP, composed of a cellular proliferation of spindle-shaped cells
accompanied by dense collagenous stroma and hemangiopericyto-
matous vasculatures. In terms of increased mitotic activity, high
cellularity, and the presence of necrosis, this tumor was considered
a low-grade malignancy from the England criteria.2 The surgical
margins of pleura, vessels, and bronchus were free of tumor cells.
Hypoglycemia improved in association with decreased serum
IGF-II early after the operation. Respiratory symptoms of the
patient decreased gradually and pulmonary function improved
(Table 1). The postoperative course was uneventful except for air
leak. The patient is alive 9 months after the operation without signs
of recurrence.
Discussion
The nonislet cell tumors, including SFTP, fibrosarcoma, mesotheli-
oma, leiomyosarcoma, and hemangiopericytoma, often cause fasting
hypoglycemia.3 Tumor-derived IGF-II is thought to be a hypoglyce-
mic agent. IGF-II is a polypeptide growth factor composed of 67
amino acid residues and shares a high degree of sequence homology
with insulin.4 The mechanism by which IGF-II induces hypogly-
cemia is not fully understood. Recent studies have shown a large
molecular form, designated big IGF-II, which is probably an
incompletely processed molecule of IGF-II and may play a key
role in the pathogenesis of nonislet cell tumor hypoglycemia.5
IGF-II produced by the tumor may act on insulin receptors, thereby
inducing hypoglycemia. The fact that the hypoglycemia reverted to
normal in association with decreased serum IGF-II after resection
of the tumor suggests this speculation, although the normal value
of serum IGF-II is unclear.
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TABLE 1. Clinical data of before and after the operation
Preop Postop
Serum glucose level (mg/dL) 49 82
Serum IGF-II (ng/mL) 549 295
PaO2 (mm Hg) 62.9 70.0
PaCO2 (mm Hg) 51.2 45.1
FEV1 (mL) 950 1210
Percent predicted FEV1 49 57
IGF-II, Insulin-like growth factor II; PaO2, arterial oxygen tension; PaCO2,
arterial carbon dioxide tension; FEF1, forced expiratory volume in 1 second.
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de Perrot and colleagues1 histologically classified SFTP as
benign and malignant types. Recurrences were reported in approx-
imately 10% of the benign groups, although the recurrence rate in
malignant groups of SFTP is high. The histologic changes of
malignancy are closely associated with prognosis of this disease.
In most cases chemotherapy and radiotherapy are not effective,
especially in malignant SFTP.
In conclusion, a complete resection improves both hypoglyce-
mia associated with serum IGF-II and relevant respiratory symp-
toms and would have a good effect on prognosis.
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Tracheobronchopathia osteochondroplastica: A rare
cause of tracheal stenosis—“TPO stenosis”
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and Andrew R. Berman,a Bronx, NY
Tracheobronchopathia osteochondroplastica, or tracheo-pathia osteoplastica (TPO), is characterized by multiplecartilaginous or bony submucosal nodules that projectinto the tracheal and bronchial lumina and may or may
not cause respiratory symptoms. The nodules always originate in
airway cartilages and typically spare the posterior membranous
wall.1
TPO was described by Wilks in the mid-1800s; by the 1970s
more than 245 cases of TPO had been reported. TPO does not
produce any characteristic symptoms or signs to indicate the
diagnosis. The disease fre-
quently manifests as chronic
cough and wheezing, which
frequently leads to the mis-
taken diagnosis of asthma or
chronic bronchitis. Many pa-
tients remain free of symp-
toms. Larger nodules project
into the airway lumen causing the commonly reported symptoms
of chronic cough, hoarseness, dyspnea, hemoptysis, and recurrent
respiratory infections. In rare instances, TPO may progress to
tracheal stenosis with critical airway obstruction.
We herein describe a case of TPO complicated by tracheal
stenosis, “TPO stenosis,” necessitating surgical resection. To date
only a handful of cases in which surgical intervention was required
have been described in the literature.2-5
Clinical Summary
A 47-year-old woman with a medical history of asthma (mild,
intermittent, occasional use of albuterol, one prior intubation) and
alcoholic liver disease presented with progressive stridor of 3
months’ duration. The patient’s symptoms had progressively wors-
ened over the past few months, and she had noted increasing
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Figure 1. Computed tomographic scan of the chest shows the
giant mass slightly compressing the heart in the right hemithorax.
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